CGI(Formerly Bioserve)

BioServe is an end-to-end genomics service provider, including bioinformatics analysis. Next Generation Sequencing (NGS) technology is quickly replacing other technologies as the gold-standard in cancer diagnostics. NGS technology can detect known genetic variants in cancer that may affect patient outcome, but is also able to pinpoint potentially actionable mutations that occur in cancer cells at much lower frequencies. BioServe India provides NGS services for cancer diagnostics and support to researchers from concept phase to validation studies in biomarker discovery. Biomarker discovery is a process by which clinically-relevant biomarkers for disease are identified so that diagnostic tests may be developed that detect the biomarker presence or level in patient samples. Bioserve has developed sequencing and data analysis pipelines for non-oncological samples.

NGS Symposium 2017

Next Generation Sequencing (NGS) has revolutionized our approach of investigating biological phenomena. It has evolved into an invaluable tool for advancing genomics research across all disciplines of biology. Microbiome status, precision medicine, molecular breeding, and systems biology rely heavily on NGS technology and have emerged as critical areas that directly impact human health. To provide recent updates on NGS technology and its applications across Agri-genomics, Onco-genomics, and model organisms, Bioserve and CCMB are jointly organizing their second Conference on Next Generation Sequencing and Bioinformatics.